REG - OptiBiotix Health - Director Appointment

OptiBiotix HealthAnnouncement

11/01/2019 07:05

RNS Number : 8127M
OptiBiotix Health PLC
11 January 2019
 


OptiBiotix Health plc
("OptiBiotix")
 
Director Appointment
 
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that, further to the previous announcement made on 17 December 2018 regarding the appointment of Frédéric Narbel as Managing Director of OptiBiotix's prebiotic division (containing SweetBiotix, OptiBiotic and microbiome modulating technology platforms), the regulatory due diligence process required for a board position has been completed. The text below sets out the required disclosures.
 
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Frédéric André Narbel (aged 34):
 




Current Appointments


Appointments in the last five years




Agropur Inc., Appleton (Wisconsin, USA), Succursale de Lancy


None




 
 
Frédéric Narbel does not currently own any shares in the Company.
 
There is no further information regarding Mr Narbel required to be disclosed under the AIM Rules.
 
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
For further information, please contact:
 




OptiBiotix Health plc


www.optibiotix.com




Stephen O'Hara, Chief Executive


Contact via Walbrook below




 


 




Cairn Financial Advisers LLP (NOMAD)


Tel: 020 7213 0880




Liam Murray / Jo Turner


 




 
finnCap (Broker)


 
Tel: 020 7220 0500




Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)


 




Camille Gochez (Corporate Broking)


 




 


 




Walbrook PR Ltd


Tel: 020 7933 8780 or optibiotix@walbrookpr.com




Anna Dunphy


Mob: 07876 741 001




 


 



 
 
 



 
 
 
 
 
About OptiBiotix - www.optibiotix.com 
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 
 
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
 
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 
 
 
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RDNZMGMMRGZGLZM